Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ:[[ticker:VRTX]]) said today that it plans to offer an estimated $375 million worth of convertible senior subordinated notes due in 2015 in a public offering. The firm has granted its underwriter, BofA Merrill Lynch, the option to purchase up to $25 million in additional notes under the same terms of the offering. Vertex, which has significant operations in San Diego, is planning to file for FDA approval of its experimental hepatitis C drug by the end of the year.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
